Vaccinating dogs to save humans
p. 94-95
Résumé
Leishmaniasis is a parasitic disease found in 90 countries, 72 of which rank amongst the world’s poorest. It is transmitted by a midge that feeds on the blood of various mammals, particularly dogs.
Texte intégral
1Leishmaniasis kills 62,000 people every year worldwide. It is however a “neglected” disease which is not within donors’ priorities. This considerably complicates research conducted on this scourge transmitted by sand flies, midges that bite humans as well as animals, particularly dogs, one of their favourite hosts. Scientists realised this when health authorities launched a campaign in Brazil to eradicate dogs infected with leishmaniasis, thereby creating a spike in human contamination as, in the absence of dogs, sand flies settle on humans instead.
••• Researchers are developing a dog vaccine against leishmaniasis •••
2This unexpected result opened a new avenue for researchers. While no one was willing to fund research on human leishmaniasis, the same could not be said for canine leishmaniasis, which threatens 25 million dogs in southern Europe. In 1990, this reality enabled researchers to raise money and finally study the leishmaniasis parasite in dogs. It took five years for them to develop a serum-free culture medium, i.e. without animal contaminant, and allow the pathogen to multiply.
3They subsequently studied how the parasite infects cells in the canine immune system and discovered a promising approach with a view to a vaccine. This vaccine does not trigger the production of antibodies but of immune cells capable of eliminating infected cells. In the parasite secretions, they isolated proteins capable of triggering this immune response. After 12 years of research and clinical tests, in 2011 they managed to bring a dog vaccine against leishmaniasis to market. At the same time, they worked together to develop a human vaccine, attempting to reduce production costs to make it available to the populations concerned. An initial human vaccine should enter into phase 1 clinical trials shortly.
“The existence of the disease must be acknowledged and integrated into the strategic plans of the ministries of health.”
Bashir Mwambi, International University of Health Sciences, Kampala, Uganda
Le texte seul est utilisable sous licence Creative Commons - Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International - CC BY-NC-ND 4.0. Les autres éléments (illustrations, fichiers annexes importés) sont « Tous droits réservés », sauf mention contraire.
Biodiversité au Sud
Recherches pour un monde durable
Jean-François Agnèse, Olivier Dangles et Estienne Rodary (dir.)
2020
Biodiversity in the Global South
Research for a sustainable world
Jean-François Agnèse, Olivier Dangles et Estienne Rodary (dir.)
2020
Trajectoires de recherches en Amazonie brésilienne
L'IRD et ses partenaires
Frédérique Seyler, Marie-Pierre Ledru et Laure Emperaire (dir.)
2022
Trajetórias de pesquisa na Amazônia brasileira
O IRD e seus parceiros
Frédérique Seyler, Marie-Pierre Ledru et Laure Emperaire (dir.)
2022
Science et développement durable
75 ans de recherche au Sud
Corinne Lavagne, Thomas Mourier, Marie-Lise Sabrié et al. (dir.)
2019
Science and sustainable development
75 years of research in the Global South
Corinne Lavagne, Thomas Mourier, Marie-Lise Sabrié et al. (dir.)
2020